Compass posts positive psilocybin data; Solstice makes $225M debut

Plus news about Luma, Inno Medicine, Schrödinger, Assembly Biosciences, Gilead, Leyden Labs, Navion, Ridge Bio, and Opus Genetics. 📊 Compass Pathways touts one-year data for psilocybin drug: The biotech’s COMP360